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Abstract
Background: Despite the high number of chikungunya cases in Indonesia in recent years, comprehensive
epidemiological data are lacking. The systematic review was undertaken to provide data on incidence, the
seroprevalence of anti-Chikungunya virus (CHIKV) IgM and IgG antibodies, mortality, the genotypes of circulating
CHIKV and travel-related cases of chikungunya in the country. In addition, a phylogenetic and evolutionary analysis
of Indonesian CHIKV was conducted.
Methods: A systematic review was conducted to identify eligible studies from EMBASE, MEDLINE, PubMed and
Web of Science as of October 16th 2017. Studies describing the incidence, seroprevalence of IgM and IgG,
mortality, genotypes and travel-associated chikungunya were systematically reviewed. The maximum likelihood
phylogenetic and evolutionary rate was estimated using Randomized Axelerated Maximum Likelihood (RAxML), and
the Bayesian Markov chain Monte Carlo (MCMC) method identified the Time to Most Recent Common Ancestors
(TMRCA) of Indonesian CHIKV. The systematic review was registered in the PROSPERO database (CRD42017078205).
Results: Chikungunya incidence ranged between 0.16-36.2 cases per 100,000 person-year. Overall, the median
seroprevalence of anti-CHIKV IgM antibodies in both outbreak and non-outbreak scenarios was 13.3% (17.7 and 7.
3% for outbreak and non-outbreak events, respectively). The median seroprevalence of IgG antibodies in both
outbreak and non-outbreak settings was 18.5% (range 0.0–73.1%). There were 130 Indonesian CHIKV sequences
available, of which 120 (92.3%) were of the Asian genotype and 10 (7.7%) belonged to the East/Central/South
African (ECSA) genotype. The ECSA genotype was first isolated in Indonesia in 2008 and was continually sampled
until 2011. All ECSA viruses sampled in Indonesia appear to be closely related
to viruses that caused massive outbreaks in Southeast Asia countries during the same period. Massive nationwide
chikungunya outbreaks in Indonesia were reported during 2009–2010 with a total of 137,655 cases. Our
spatio-temporal, phylogenetic and evolutionary data suggest that these outbreaks were likely associated with
the introduction of the ECSA genotype of CHIKV to Indonesia.
Conclusions: Although no deaths have been recorded, the seroprevalence of anti-CHIKV IgM and IgG in the
Indonesian population have been relatively high in recent years following re-emergence in early 2001. There is
sufficient evidence to suggest that the introduction of ECSA into Indonesia was likely associated with massive
chikungunya outbreaks during 2009–2010.
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Background
Arboviruses (arthropod-borne viruses) are a group of
viruses that exist in a transmission cycle between
blood-feeding arthropod vectors and amplifying, verte-
brate hosts. With most arboviruses, human involvement
in this transmission cycle is incidental [1]. In terms of
public health significance, the mosquito is the most
important vector of arbovirus transmission. It is esti-
mated that approximately 3.9 billion people, living in
more than 120 different countries, are at risk of becom-
ing infected with any of the three major arboviruses:
Chikungunya virus (CHIKV), Dengue virus (DENV) and
Zika virus (ZIKV) [2]. Chikungunya virus, which is pri-
marily transmitted by Aedes aegypti and Ae. albopictus
mosquitoes, is a positive-sense single-stranded RNA
virus and a member of the family Togaviridae [3, 4]. The
first well-characterised chikungunya outbreak was re-
ported in Southern province, Tanganyika territory of
Tanzania in 1952 [5, 6]. Sporadic chikungunya outbreaks
were subsequently identified in parts of Africa and Asia
during the 1950s and 1960s, followed by an apparent
re-emergence in the 2000s [7]. Since 2005, large-scale
outbreaks of chikungunya sweeping across south-west-
ern Indian Ocean and Southeast Asia [8–20]. In La
Réunion, the outbreak affected about a third of the
population [9, 21] and in India, the viruses infected
more than 1.3 million persons during 2005–2006 [14].
In Sri Lanka, the viruses infected more than 100,000
people [15] and CHIKV subsequently spread to
Southeast Asia including Indonesia.
The illnesses caused by CHIKV and DENV are clinic-
ally indistinguishable and the accurate diagnosis of these
infections on clinical grounds alone is usually problem-
atic [22, 23]. Although prior literature has stated that a
higher proportion of people infected with CHIKV are
symptomatic than those infected with DENV [24], a
recent systematic review revealed that asymptomatic
chikungunya had a very high variability in percentages
ranging from 3.2% in La Réunion (2005–2006) to 82.1%
in the Philippines (2012–2013) [25]. The highest
percentage of asymptomatic chikungunya have been
recorded with the Asian genotype in the Philippines with
82.1% [26]. The common symptoms of chikungunya
include rash, high fever, severe joint and muscle pain,
headache and photophobia [7, 27]. Severe symptoms,
involving vital organs, may develop during CHIKV
infection such as encephalitis [28, 29], encephalopathy
[29–31], optic neuropathy [29, 32], neuroretinitis [32],
myelopathy and myelitis [29], Guillain-Barré syndrome
[29, 32], myocarditis [31], hepatitis [33], acute interstitial
nephritis [34], severe sepsis [35], septic shock [35] and
multi-organ failure [31–33, 36, 37]. In rare cases, infec-
tions may be fatal [28, 33–35, 37]. Perinatal CHIKV in-
fection can cause sequelae such as microcephaly and
cerebral palsy [38]. In adults, persisting arthralgia/arth-
ritis, alopecia and depression are the most commonly
recorded sequelae [39–42]. A meta-analysis found that ap-
proximately 25% of chikungunya cases develop chronic in-
flammatory rheumatism and 14% develop chronic
arthritis [43], creating a major burden on society in terms
of morbidity and economic productivity [41, 42, 44, 45].
CHIKV has an approximately 12 kb genome that en-
codes four non-structural proteins (NSP1–4) and five
structural proteins (C, E3, E2, 6 K, and E1) [4]. Genetic
analysis has identified three genotypes of CHIKV: the
West African, East/Central/South African (ECSA), and
Asian genotype [46]. The ECSA genotype consists of
three lineages: Central African, East/South African, and
the Indian Ocean lineage. These genotypes are spreading
sporadically worldwide, with ECSA and Asian genotypes
being the predominately isolated [47].
In Indonesia, based on official documents from the
Ministry of Health (MoH), chikungunya cases were
reported for the first time in Samarinda (Kalimantan is-
land) in 1973 [48]. However, there is evidence to suggest
that CHIKV infections have occurred in Indonesia prior
to 1973. Serum samples collected between 1969 and
1972 demonstrated significant titres of anti-CHIKV anti-
bodies when tested using haemagglutination inhibition
assay (HI) and the plaque reduction neutralization test
(PRNT) in most of the Indonesian archipelago, except
Java [49, 50]. In addition, evidence from historical
reports suggest that the first circulation of CHIKV was
back in 1779 in Jakarta, when this infection called as
kidinga pepo [51, 52]. This is widely acknowledged by
experts in the field of arboviruses as the first report of
chikungunya in Indonesia, although it is impossible to
demonstrate by molecular clock analysis [53]. The first
virologically confirmed chikungunya outbreak was re-
ported in June 1982 in Jambi province of Sumatra island,
followed by multiple outbreaks between 1983 and 1984
[54]. Chikungunya cases were not recorded in Indonesia
for approximately 20 years, before the infection appeared
to re-emerge and cause multiple outbreaks in South
Sumatera, Aceh and West Java in early 2001 [48]. Since
then multiple outbreaks have been reported [48, 55–65].
Despite the high number of chikungunya cases in
Indonesia in recent years, comprehensive epidemio-
logical data are lacking.
Objectives
The overarching aim of the study was to provide a com-
prehensive overview of chikungunya epidemiology in
Indonesia including an evolutionary analysis of CHIKV
that have circulated in the country between 1983 and
2016. Through a systematic review of available literature
and available sequence data on GenBank, the primary
objectives of this study were: a) to estimate the incidence
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of chikungunya in Indonesia; b). to characterize the sero-
prevalence of anti-CHIKV IgM and IgG antibodies in
Indonesia; c) to describe the mortality of chikungunya in
Indonesia and; d) to genetically characterize CHIKV
circulating in Indonesia that were isolated locally or
from travelers returning from Indonesia. The secondary
objective was to provide data of travel-associated chi-
kungunya originating from Indonesia.
Methods
Protocol and registration
The systematic review was conducted as recommended
by the Preferred Reporting Items for Systematic Reviews
and Meta-analyses (PRISMA) guidelines [66]. The
protocol of the systematic review was registered at
PROSPERO, an international database of prospectively
registered systematic reviews at the University of York
(CRD42017078205).
Role of the funding source
The funders of the study had no role in study design,
data collection, data analysis, data interpretation, writing
of the report and decision to publish.
Eligibility criteria
In this study, all full articles or abstracts published in
any year and language were included while editorials,
reviews, commentaries, and qualitative studies were ex-
cluded for all outcomes except for mortality. This is be-
cause study reporting chikungunya mortality is limited.
Studies in any setting (outbreak or non-outbreak) with
any study design (cross-sectional or prospective) were
considered eligible.
Chikungunya incidence
Any publications that reported the number of acute
chikungunya infections or seroconversions over any time
interval were eligible, as proposed previously [67]. Stud-
ies reporting chikungunya outbreaks with an attack rate
were also considerate eligible if information about the
population at risk was given.
Seroprevalence of anti-CHIKV IgM and IgG antibodies
Any publications that provided primary data on the
seroprevalence of anti-CHIKV IgM and IgG antibodies
in Indonesia were considered eligible. Eligible studies
included those reporting anti-DENV IgM and/or IgG
seroprevalence, measured by the presence of IgM and
IgG antibodies, among individuals with suspected acute
chikungunya infection, with suspected other arbovirus
infection, with undifferentiated acute febrile illness or
who were healthy. Studies reporting anti-DENV IgM
and/or IgG during outbreak and non-outbreak settings
were considered eligible.
Chikungunya mortality
Studies reporting chikungunya-associated deaths either
during an outbreak or in a non-outbreak setting were
considered eligible. For mortality, all type of articles (full
papers, case studies, letters, editorials, and commentar-
ies) with adequate information were considered eligible.
Studies reporting chikungunya-associated death among
travellers returning from Indonesia were excluded.
Chikungunya virus genotype
All CHIKV sequences originating from Indonesia, either
isolated locally or in travellers returning from Indonesia,
were included. CHIKV sequences originating from
Indonesian mosquito samples were also included. Single
and partial gene sequences, of either non-structural or
structural genes, as well as complete genome sequences
were included. Studies reporting CHIKV genotype infor-
mation, that failed to deposit sequence data into
GenBank, were excluded.
Exported chikungunya
All chikungunya cases reported in travellers returning
from Indonesia were included. Cases were confirmed by
anti-CHIKV IgM, reverse transcription polymerase chain
reaction (RT-PCR) or viral isolation. Cases without
laboratory confirmation were excluded.
Information sources and search strategy
A systematic search was conducted using four biblio-
graphical databases (EMBASE, MEDLINE, PubMed and
Web of Science as of October 16th 2017) to identify poten-
tial articles using Medical Subject Headings (MeSH)
encompassing the terms “Chikungunya” AND “Indonesia”.
No limit was set for the publication year or language. In
addition, grey literature and official reports from the MoH,
published in either Indonesian or English, were included.
Reference lists of the identified articles and references of
deposited sequences in GenBank were also searched
manually to find additional potential studies. Some authors
were contacted to obtain or clarify information.
Study selection
All titles and abstracts of identified articles were imported
into the local library of EndNote X7 (Thompson Reuters,
Philadelphia, PA, USA) and duplicate records between
multiple databases were removed. Retrieved articles were
initially screened based on title and abstract to identify
possible eligible studies. The full texts of potential eligible
articles were then reviewed. The screening and review
process was conducted by two authors (HH and AM).
After reviewing full texts, the eligibility of each study was
decided. If there was disagreement between two authors, a
third made the final decision.
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Data collection process and synthesis
Chikungunya incidence
The number of new chikungunya cases and population
at risk or overall attack rate during an outbreak were re-
corded. Location, date, setting of study, diagnosis method,
number of confirmed or suspected cases and other related
information were also extracted. The incidence of chikun-
gunya was expressed in terms of person-year.
Besides systematically reviewing the available litera-
ture, we also accessed and extracted data from the
National Disease Surveillance run by the Directorate
General of Disease Prevention and Control of the
Indonesian MoH. Chikungunya is a notifiable disease in
Indonesia. The chikungunya case definition and case as-
certainment used in this surveillance system have
previously been published at the National Guideline for
Prevention and Control of Chikungunya from MoH
[68]. This case definition follow the World Health
Organization (WHO) criteria [69]. In brief, chikungunya
cases were classified into three categories: a) possible
case, diagnosed based on clinical criteria alone as acute
onset of fever > 38.5°C and severe arthralgia/arthritis not
explained by other medical conditions; b) probable case,
diagnosed based on the clinical criteria as mentioned
and epidemiological criteria (residing or having visited
epidemic areas) and; c) confirmed case, diagnosed based
on laboratory criteria which show a positive result for
virus isolation, RT-PCR, IgM antibodies or a four-fold
increase in IgG antibodies [68]. This surveillance system
includes all types of chikungunya cases. The number of
chikungunya cases were retrieved from the database.
This primary dataset was analysed separately from other
studies from systematic review. The annual chikungunya
incidence rate was determined by dividing the number
of new chikungunya cases, by the size of the population
at risk based on MoH data. The incidence rate was
expressed as per 100,000 person-years. To obtain a more
comprehensive distribution of the chikungunya cases in
Indonesia, geographical maps of provincial incidence
rates from 2008 to 2016 were created using ArcGIS
software [70]. The provincial incidence rate was
expressed as the number of chikungunya cases per
100,000 civilians.
Seroprevalence of anti-CHIKV IgM and IgG antibodies
Because each study had different settings, designs and
tested sera (collected from febrile or non-febrile sub-
jects), which may potentially affect the percentage of
prevalence, the seroprevalence in this study was strati-
fied. The seroprevalence of anti-CHIKV IgM and IgG
antibodies were divided into: a) setting of study (out-
break and non-outbreak) and; b) status of tested sera
(collected from healthy individuals and patients with un-
differentiated acute febrile illness or suspected arbovirus
infection). Therefore, the seroprevalence of anti-CHIKV
IgM and IgG antibodies were stratified into four categor-
ies: a) among febrile patients during a chikungunya
outbreak or post outbreak; b) among non-febrile patients
during a chikungunya outbreak or post outbreak; c)
among febrile patients not in an outbreak; and d) among
non-febrile patients not in an outbreak. If one reference
consisted of two or more studies with different settings
or statuses of participants, then the data were divided
into the relevant categories. The median value and the
ranges of the seroprevalence of IgM and IgG antibodies
were calculated for each setting.
Chikungunya mortality
For mortality, the number of deaths associated with
CHIKV infections either during an outbreak or in a
non-outbreak setting was included. Data such as loca-
tion, date, setting of study, sample size, diagnosis
method, number of cases and other related information
were extracted. The case fatality rate was calculated as
the number of deaths associated with chikungunya,
confirmed by doctor resume on death certificate during
passive surveillance or confirmation by outbreak investi-
gation staff run by MoH, divided by the number of
cases, expressed as a percentage (%). All deaths associ-
ated with chikungunya are reported continuously in the
National Disease Surveillance managed by MoH.
Chikungunya virus genotype
To determine the CHIKV genotype, CHIKV sequences
derived from locals and travellers returning from
Indonesia were included. In addition, a search was
conducted in GenBank to confirm the findings from sys-
tematic review and to obtain additional sequence data.
To avoid missing sequences from our search on
GenBank especially from travel-related cases, for ex-
ample unlabelled origin of sequences, intensive manual
search was conducted on references from the systematic
review. Then manual searches were conducted in Gen-
Bank. Authors were contacted if there was disagreement
between the information in the article and with the
GenBank data. To provide more comprehensive data of
circulating genotype over time, data from a study that
consisted of genotype data over multiple years was
divided and reported per year. Sequences were extracted
and imported to Geneious v.10.1.3 [71] for further
phylogenetic analysis.
Exported chikungunya
To fully assess epidemiology data of chikungunya in
Indonesia, all confirmed CHIKV infections (as defined
by serology or RT-PCR) reported from other countries
that are known to have originated from Indonesia were
also included. Essential data such as date, country, and
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number of cases, diagnosis method, and the genotype of
CHIKV were collected. Data from a study that consisted
of genotype data over multiple years were also divided
and reported per year, if possible.
Outcomes
The primary outcomes of the systematic review, together
with MoH database analysis, were: a) the incidence of
chikungunya in Indonesia; b) the seroprevalence of
anti-CHIKV IgM and IgG antibodies in Indonesia; c)
chikungunya-related mortality in Indonesia and; d) a
description of the CHIKV genotypes circulating in
Indonesia. The secondary outcome was chikungunya
cases exported from Indonesia to other countries.
Risk of bias assessment
The quality of eligible studies of incidence and sero-
prevalence IgM and IgG was evaluated by evaluating the
risk of bias and the precision of the reported measures
in accordance with a modified tool from previous study
[67]. The risk of bias was evaluated by critically apprais-
ing diagnostic methods, sampling, response rate, and
study setting. Studies were considered to have a low,
high, or unclear risk of bias based on those four
domains. Risk of bias was considered low if: a) sero-
prevalence of CHIKV-specific antibodies was measured
using a standard method such as enzyme-linked im-
munosorbent assay (ELISA), HI, and PRNT-based assays
and chikungunya was diagnosed with laboratory con-
firmation such as IgM, RT-PCR or viral isolation; b)
samples was selected using probability-based strategy -
for incidence studies that enrolled individuals presenting
to a health facility with acute infection this domain was
not assessed; c) response rate was ≥80% and; d) the
study setting was clearly stated (during outbreak or not).
Studies were considered to have high precision if the
number of individuals recruited or tested was ≥100 [67].
For genotyping studies, the quality of study was judged
based on: a) whether the origin of sequences is clearly
mentioned (human or mosquito) and; b) whether the lo-
cation and date of isolation are clearly provided. The
quality of studies about exported chikungunya was
assessed based on two criteria: a) clear information of
travel history and; b) chikungunya cases were diagnosed
using standard methods such as IgM, RT-PCR or viral
isolation. If at least one criterion was missing in studies
on genotyping or exported chikungunya, then the study
was considered to have a high risk of bias. If a reference
consists more than one studies, the risk of bias was
assessed for each study.
Phylogenetic and evolutionary analysis
To provide solid data on CHIKV circulating in
Indonesia, phylogenetic and evolutionary analyses were
conducted for all Indonesian CHIKV sequences. To
achieve this, Indonesian CHIKV sequences were down-
loaded from the GenBank database using the search key-
words: “Chikungunya” AND “Indonesia” (last searched:
October 20th, 2017). For comparison, all CHIKV se-
quences from other countries were also downloaded and
those full genome sequences were trimmed leaving only
the E1 gene. All Indonesian and comparison sequences
were aligned using a Multiple Alignment using Fast
Fourier Transform (MAFFT) v.7.309 [72] as imple-
mented in Geneious v.10.1.3 [71]. To provide the rela-
tionship between Indonesian viruses and viruses isolated
from other parts of world, an estimation of the max-
imum likelihood-based phylogenetic tree was performed
using Randomized Axelerated Maximum Likelihood
(RAxML) v.7.2.8 [73, 74]. General Time Reversible with
gamma substitution model (GTR + Γ) and a rapid boot-
strap procedure were employed with 1589 comparison
sequences.
To provide evolutionary information of Indonesian
viruses, their evolutionary rate and the Time to Most
Recent Common Ancestors (TMRCA) was estimated
using the Bayesian Markov chain Monte Carlo (MCMC)
method as implemented in Bayesian Evolutionary
Analysis Sampling Trees (BEAST) v.2.4.6 [75]. The input
file for BEAST was prepared using Bayesian Evolution-
ary Analysis Utility (BEAUti) and runs were performed
using General Time Reversible with four gamma cat-
egory and invariant sites (GTR + Γ4 + I). The runs used
the relaxed lognormal molecular clock with an initial
estimated evolutionary rate of 4.33 × 10− 4 substitutions
per site per year [76] and with a Coalescent Bayesian
skyline model. A hundred million chains were run and
sampled every thousand cycles with 53 representative
reference sequences. The output of MCMC runs was an-
alyzed using Tracer v.1.6 to assess effective sampling
size. The Maximum Clade Credibility (MCC) of phylo-
genetic trees was created using TreeAnnotator v.2.4.6
with 10% burn-in and visualized using FigTree v.1.4.3.
Results
Study eligibility results
The searches yielded 182 references of which 84 were
excluded as duplicates. After conducting a title and ab-
stract screen of 98 references, an additional 55 refer-
ences were excluded (Fig. 1). The full text references
were retrieved for 43 titles; 19 had been excluded for
one of four reasons: a) the full-text did not include data
of any outcome of interest (n = 9); b) full-texts were not
available and the abstract did not include adequate data
for any outcome of interest (n = 8); c) duplicated data in
another study (n = 1); and d) did not meet eligibility cri-
teria (n = 1). This screen resulted in 24 eligible studies
[13, 49, 50, 54, 55, 77–95]. An additional 16 references
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were identified from reference lists, reviews and Gen-
Bank references [20, 23, 76, 96–108] in which some of
the references reported more than one of the outcomes
of interest. A total of 40 references were included in the
systematic review [13, 20, 23, 49, 50, 54, 55, 76–108]. Of
these references, two studies assessed the incidence of
chikungunya [94, 95], five studies assessed the seropreva-
lence of anti-CHIKV IgM antibodies [54, 55, 77, 78, 95]
and seven assessed the seroprevalence of anti-CHIKV IgG
antibodies [49, 50, 54, 55, 77–79]. Five studies reported
mortality rates of chikungunya [13, 54, 55, 78, 80]. Geno-
type analyses of CHIKV circulating in Indonesia were re-
ported in sixteen studies [13, 20, 23, 76, 78, 81–85, 94, 98,
100, 102, 103, 108], and exported chikungunya or
travel-related chikungunya were reported in 24 studies
[20, 23, 82, 84, 86–93, 96–107]. Detailed characteristics of
each study is provided in Additional file 1. In addition,
eleven official reports from the MoH of Indonesia, all
reporting the incidence and mortality of chikungunya,
were identified [48, 56–65].
Precision and risk of bias assessment
Quality assessment for each study included on chikun-
gunya incidence and seroprevalence anti-CHIKV IgM
and IgG is provided in Table 1. Both chikungunya inci-
dence studies, four out five (75%) and five out seven
(71.4%) of references of seroprevalence anti-CHIKV IgM
and IgG, respectively, contained high precision as
defined by a sample size of > 100 subjects. For the risk
of bias assessment, response rate was not reported in all
studies and all studies used valid essay. Among sero-
prevalence studies, 16% (2/12) studies used probability
sampling (i.e. low risk of bias) and all studies had
clear setting of the study. There was no variability of
risk of bias among studies on CHIKV genotype in
Indonesia and exported chikungunya cases. All studies
on CHIKV genotypes provided clear information of
sequences (origin of the sequences, location and date
of isolation) and all exported chikungunya studies had
robust methods in diagnosing chikungunya and clear
information of travel history (i.e. low risk of bias).
Fig. 1 Flowchart of the result of literature search according to the preferred reporting items of systematic reviews and meta-analyses (PRISMA)
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See Additional file 1 for detailed risk of bias assess-
ment for each study.
Incidence of chikungunya
Two studies assessed the incidence of chikungunya in
Indonesia [94, 95]. One study took place in Bandung
(West Java province) between 2000 and 2004 and
between 2006 and 2008 [94]. This study found that the
incidence of chikungunya was 10.1/1000 persons-year
[94]. Another study in three localities in Indonesia found
similar incidence, 8.8/1000 persons-year during 2010–
2011 [95]. In addition, eleven annual reports from the
MoH of Indonesia were identified [48, 56–65], providing
the incidence rate of chikungunya between 2004 and
2015. This data revealed that the lowest chikungunya in-
cidence was in 2005 with 0.16/100,000 person-year [48]
while the highest incidence rate was recorded in 2009
with 36.2 cases per 100,000 persons-year [62]. In 2009,
more than 83 thousand cases were reported and CHIKV
been reported circulate in seventeen out of 34 provinces
in Indonesia [62].
To provide a more comprehensive picture of incidence
rate of chikungunya, we accessed and extracted the
National Disease Surveillance database at the MoH. The
database covered chikungunya incidence between 2001
and 2016. In this 16-year period, the highest number of
chikungunya cases was recorded in 2009 with 83,756
cases, equivalent to an incidence rate of 36.2 cases per
100,000 person-year (Fig. 2). The map of provinvial indi-
cence rates indicated that chikungunya cases did not dis-
tribute equally among Indonesian regions (Fig. 3). The
highest incidence of chikungunya occurred in Sumatera,
Kalimantan and Java. Chikungunya was not reported in
Papua and West Papua province of Indonesia between
2008 and 2016.
Seroprevalence of anti-CHIKV IgM antibodies
Five studies were identified that assessed the seropreva-
lence of anti-CHIKV IgM antibodies (with or without
the combination of other tests), during both outbreak
and non-outbreak settings [54, 55, 77, 78, 95]. These
studies analyzed a total of 1183 serum samples between
1998 and 2010. The combination of all studies that were
conducted in outbreak and non-outbreak settings
yielded a median IgM seroprevalence of 13.3% (range
0.0–60.4%) (Table 2).
Our data indicate that the seroprevalence of
anti-CHIKV IgM antibodies during an outbreak is much
higher compared to in a non-outbreak setting (median
17.7%, range 3.2–60.4% vs. median 7.3%, range 0.0–26.3%,
respectively). In some outbreaks the seroprevalence of
IgM antibodies was more than 50%, such as the outbreak
in Bogor 2001 [55]. However, an investigation conducted
3 months after a chikungunya outbreak in Yogyakarta
during 1998–1999 found that IgM antibodies were only
Table 1 Precision and risk of bias assessment of studies on chikungunya incidence and seroprevalence of anti-Chikungunya virus in
Indonesia
Year Region Sample Risk of bias Precision Reference
Assay Sampling Setting Response rate
Chikungunya incidence studies
2000–2004 Bandung 5704 Low NA Low Unknown High [94]
2010–2011 Jakarta, West Java, Bali 446 Low NA Low Unknown High [95]
Seroprevalence anti-CHIKV IgM studies
2015–2016 Bali 15 Low NA Low Unknown Low [78]
2004–2005 Indonesia 198 Low NA Low Unknown High [77]
2010 Jakarta, West Java, Bali 105 Low NA Low Unknown High [95]
2001 Bogor 99 Low Low Low Unknown Low [55]
1998–1999 Yogyakarta 76 Low Unknown Low Unknown Low [54]
Seroprevalence anti-CHIKV IgG studies
2015 Bali 8 Low NA Low Unknown Low [78]
2004–2005 Indonesia 198 Low NA Low Unknown High [77]
1995–1996 Semarang 60 Low NA Low Unknown Low [97]
1998–1999 Yogyakarta 76 Low Unknown Low Unknown Low [54]
2002 Bekasi 145 Low Low Low Unknown High [55]
1972 Ambon 321 Low Unknown Low Unknown High [50]
1972 Kalimantan 199 Low Unknown Low Unknown High [49]
NA Not applicable
Harapan et al. BMC Infectious Diseases          (2019) 19:243 Page 7 of 20
present in 3.2% of suspected patients with CHIKV infec-
tion while IgG seroprevalence was at 70.4% [54] (Table 2).
Seroprevalence of anti-CHIKV IgG antibodies
Seven studies provided information on the seroprevalence
of anti-CHIKV IgG antibodies in humans, in both out-
break and non-outbreak settings [49, 50, 54, 55, 77–79].
These studies covered a 47-year period (between 1969 and
2015) with a total of 3717 serum samples tested (Table 3).
Overall, in both outbreak and non-outbreak settings, the
median seroprevalence of IgG antibodies was 18.5% (ran-
ging from 0.0% in non-febrile inhabitants in non-outbreak
area to 73.1% among patients who were febrile during an
outbreak). In a non-outbreak setting, for both febrile and
non-febrile patients, the median seroprevalence of
anti-CHIKV IgG was 14.1% (range 0.0–43.9%). In con-
trast, the seroprevalence of IgG antibodies was much
higher among patients during an outbreak (both febrile
and non-febrile individuals) (median 47.4%, range 0.0–
73.1%). The median seroprevalence of anti-CHIKV IgG
among non-febrile subjects in a non-outbreak setting was
12.2% (range 0.0 to 26.8%) in Indonesia.
Mortality of chikungunya in Indonesia
Five outbreak investigations [13, 54, 55, 78, 80] were iden-
tified and no deaths due to chikungunya were reported. In
addition, in eleven annual reports from the MoH of
Indonesia, covering 44 years (1973 to 2016), there was no
deaths related to CHIKV infection [48, 56–65].
Genotypes of CHIKV circulating in Indonesia
Sixteen studies reporting the genotype of circulating
Indonesian CHIKV were identified with a total of 130
viruses sequences [13, 20, 23, 76, 78, 81–85, 94, 98, 100,
102, 103, 108] (Table 4). Of these studies, seven were con-
ducted among local inhabitants [13, 78, 81, 83, 85, 94, 108],
and eight were conducted with viruses isolated from
travellers returning from Indonesia [20, 23, 82, 84, 98,
100, 102, 103]. One study did not mention whether
the virus was isolated in local inhabitant or in a trav-
eller [76]. Of the seven local studies, four were con-
ducted in a non-outbreak setting [81, 83, 85, 94], two
investigations were carried out during a chikungunya
outbreak [13, 78] and one study did not specify the
setting [108]. Most of the viruses that were isolated
from travellers were from Taiwan [23, 82, 100]. Other
viruses were collected from travellers returning to
Singapore [20], France [98], the Netherlands [102],
Russia [84], and Germany [103]. A vast majority of
the 130 CHIKV isolated from Indonesia, belonged to
Asian genotype (92.3%, 120/130). The remaining
isolated viruses were identified as being viruses of the
ECSA genotype (7.7%, 10/130). Of these ECSA vi-
ruses, two were isolated locally in 2011 [13] and the
remaining eight were isolated from travelers returning
from Indonesia between 2008 and 2010 [20, 23, 102].
Viruses of the West African genotype have not yet
been identified in or from Indonesia.
To confirm the results of the search from systematic
review for CHIKV genotype literature and the database,
a search was conducted in GenBank which yielded 119
sequences, rather than the expected 130 sequences.
Discrepancy between these findings is due to three
reasons: a) eight sequences were from an in press study
and had not yet been deposited into GenBank when
the search was conducted [85]; b) two sequences of
CHIKV, which were isolated from Singaporean trav-
elers returning from Indonesia, were deposited into
Fig. 2 Trends of number of chikungunya cases and incidence rates of chikungunya case (per 100,000 person years) reported to the Ministry of
Health of the Republic of Indonesia from 2001 to 2016
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GenBank as Singaporean viruses [20] and; c) one se-
quence had no information of country of origin in
GenBank.
For phylogenetic and evolutionary analyses based on
CHIKV E1 gene sequences, 127 sequences were in-
cluded. One paper, reporting non-structural gene se-
quence of three Asian genotype viruses, was excluded
[81]. The relationship of Indonesian CHIKV to other
CHIKV isolated worldwide is shown in Fig. 4. The Asian
genotype was first identified in Indonesia in 1983 [76],
while viruses of the ECSA genotype were isolated for the
first time in 2008, following the isolation of this geno-
type from returning Taiwanese [100] and Singaporean
travellers [20].
MCMC analysis using 53 representative reference
sequences reveals that the ECSA viruses sampled in
Indonesia between 2008 and 2011 belong to the Indian
Ocean Lineage (IOL) and are closely related to viruses
that have circulated in Southeast Asian countries such
as Sri Lanka, Malaysia, Singapore, Thailand, and Myanmar,
as well as China and South Korea during the same period
(Fig. 5). Interestingly, viruses of the ECSA genotype have
not been sampled in Indonesia, either in local or from
travelers studies, from 2011 onwards.
Exported chikungunya cases
Twenty four studies, reporting exported chikun-
gunya cases that originated from Indonesia covering
a 26 year-period from 1989 to 2014, were identified
[20, 23, 82, 84, 86–93, 96–107] (Table 5). During
this period, a total of 195 cases of chikungunya
cases were reported from travellers returning from
Fig. 3 Geographical mapping of incidence rates of Chikungunya virus infection in Indonesian provinces from 2008 to 2016 (per 100,000 persons).
Annual number of chikungunya cases from each Indonesian province was extracted from the Ministry of Health of the Republic Indonesia and
the map was created using ArcGIS. The colour gradation indicates the incidence rates
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Australia (128 cases) [86–88, 99, 104–107], Taiwan
(47 cases) [23, 82, 100], Japan (4 cases) [89, 90] and
other countries in Asia, Europe and the Pacific region (16
cases) [76, 84, 91–93, 96, 98, 101–103, 109]. Most of these
cases were diagnosed with a combination of serology and
RT-PCR, and sequence data was generated from only
27.6% (54/195) of cases [20, 23, 82, 84, 98, 100–103].
Discussion
Our systematic review and analysis of MoH database
examine the epidemiology of chikungunya in Indonesia
by summarizing published studies on chikungunya inci-
dence, the seroprevalence of IgM and IgG, mortality,
CHIKV genotypes and exported cases. Existing literature
on incidence rate of chikungunya Indonesia is lacking.
Nevertheless, using MoH databases, we are able to
generate comprehensive incidence rates of chikungunya
in Indonesia over a 16 year period, from 2001 to 2016.
Incidence data indicate there is no typical pattern of
chikungunya in the country. The most notable finding is
the massive nationwide outbreak during 2009–2010 with
137,655 cases followed by a smaller nationwide outbreak
in 2013 with 15,324 cases (Fig. 2). Prior to 2008 the inci-
dence of chikungunya was less than 10,000 cases/year
and this increased significantly in 2009 and 2010 with
83,756 and 53,899 cases, respectively [61, 62] (Fig. 2) in-
dicating that chikungunya incidence increased more
than 20 times in 2009. There is no scientific evidence to
explain what occurred during this outbreak. The MoH
suggests that this increase was due to the fact that prior
to 2009, many regions did not include CHIKV case
reports in their annual reports to the MoH.
Despite the multiple outbreaks that have occurred in
Indonesia since its re-emergence, there is also a lack of
data regarding the magnitude of CHIKV exposure in the
Indonesian population. Our systematic review, covering
the period of 1998–2010, indicates that CHIKV-specific
IgM antibodies were detected approximately 13% of sera
collected from healthy and acute febrile illness patients
(range 0.0–60.4%). This estimate can be interpreted as
evidence of recent CHIKV infection. Although IgM may
persist for months to years following the resolution of
infection, IgM titers reduce to undetectable levels after
weeks for most chikungunya patients and are replaced
with long lasting IgG [4]. The high seroprevalence of
anti-CHIKV IgM indicates that chikungunya is endemic
in Indonesia with on-going transmission.
Interestingly, 10.8% of sera from febrile patients
(presenting with dengue-symptoms or undifferentiated
acute febrile illness) in a non-outbreak setting had
anti-CHIKV IgM [77, 95]. This finding suggests that
many patients presenting with dengue-like symptoms
had a CHIKV infection. This proposed consideration is
supported by the evidence from other studies: a) in a
Table 2 Seroprevalence of anti-Chikungunya virus IgM antibodies within certain Indonesian location as reported in published
papers






Non-outbreak and febrile 2010 Jakarta, West Java, Bali 105 26 24.8 IgM ELISA [95]
2004–2005 Indonesia 198 7 3.5 IgM ELISA [77]
1998–1999 Yogyakarta 57 15 26.3 IgM ELISA [54]
Non-outbreak and non-febrile 2002 Bekasi 55 0 0.0 IgM ELISA [55]
2001 Bogor 99 9 9.1 IgM ELISA [55]
1998–1999 Yogyakarta 123 7 5.6 IgM ELISA [54]
Median (Non-outbreak) 1998–2010 Indonesia 7.3 (0.0–26.3) IgM ELISA Present study
Outbreak and febrile 2015–2016 Bali 15 2 13.3 IgM ELISA [78]
2002 Bekasi 93 40 43.0 IgM ELISA [55]
2001 Bogor 86 52 60.4 IgM ELISA [55]
1998–1999 Yogyakarta 61 2 3.2 IgM ELISA [54]
Outbreak and non-febrile 2002 Bekasi 124 13 10.4 IgM ELISA [55]
2002 Bekasi 21 4 19.0 IgM ELISA [55]
2001 Bogor 45 8 17.7 IgM ELISA [55]
2001 Bogor 25 12 48.0 IgM ELISA [55]
1998–1999 Yogyakarta 76 3 3.9 IgM ELISA [54]
Median (Outbreak) 1998–2010 Indonesia 17.7 (3.2–60.4) IgM ELISA Present study
Median (Total) 1998–2010 Indonesia 13.3 (0.0–60.4) IgM ELISA Present study
ELISA Enzyme-linked immunosorbent assay
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non-outbreak setting, approximately 10% of febrile
patients with dengue-like symptoms demonstrated titers
of anti-CHIKV IgM [110]; and b) in most Asian coun-
tries, DENV and CHIKV co-circulate in the same loca-
tion [111, 112]. The confusion between dengue and
chikungunya infection could explain underreporting of
CHIKV in Indonesia [113]. Therefore, further tests is
required to exclude CHIKV infection in patients with
dengue-like symptoms. However, many regions in
Indonesia lack a specific diagnostic test for chikun-
gunya. In clinical settings in Indonesia, however,
DENV infection must be considered first as the main
diagnosis to minimize the incidence of severe forms
of dengue and therefore to reduce dengue mortality.
This rationale is based on the fact that dengue more
frequently presents with severe forms compared to
CHIKV, and has a high mortality rate in Indonesia
[114].
We found that in both outbreak and non-outbreak
localities, the median seroprevalence of asymptomatic
residents with current CHIKV infection (the present of
IgM) was 9.1% (range 0.0–48.0%) (Table 2). This finding
highlights the important fact that not all CHIKV infec-
tions present with specific symptoms that are noticed by
the infected individuals. A recent systematic review
revealed that the proportion of CHIKV infections that
were asymptomatic was highly variable, ranging from 3.2
to 82.1% [25]. Interestingly, current studies indicate
there is an increasing trend of asymptomatic chikun-
gunya over time [7, 21, 27]. Except for one study, all
Table 3 Seroprevalence of anti-Chikungunya virus IgG antibodies within certain Indonesian location as reported in published papers






Non-outbreak and febrile 2004–2005 Indonesia 198 87 43.9 IgG [77]
1995–1996 Semarang 60 14 23.3 IgG [79]
1998–1999 Yogyakarta 57 24 42.1 IgG [54]
Non-outbreak and non-febrile 1998–1999 Yogyakarta 123 33 26.8 IgG [55]
2002 Bekasi 55 3 5.4 IgG [55]
2001 Bogor 99 13 13.1 IgG [55]
1972 Kalimantan 692 151 21.8 HI [50]
1972 Java 54 0 0.0 HI [51]
1972 Bali 107 2 1.9 HI [51]
1972 Lombok 140 6 4.3 HI [51]
1972 Kupang 121 15 12.4 HI [51]
1972 Sulawesi 298 55 18.4 HI [51]
1972 Ambon 321 37 11.5 HI [51]
1972 Kalimantan 199 28 14.1 PRNT [50]
1971 Sulawesi 125 24 19.2 PRNT [50]
1971 Ambon 64 2 3.1 PRNT [50]
1969–1970 Papua 243 45 18.5 PRNT [50]
Median (Non-outbreak) 1969–2005 Indonesia 14.1 (0.0–43.9) Present study
Outbreak and febrile 2015 Bali 8 0 0.0 IgG [79]
2002–2003 North Sulawesi 222 18 8.1 IgG [56]
2002 Bekasi 93 68 73.1 IgG [56]
2001 Bogor 86 58 67.4 IgG [56]
1998–1999 Yogyakarta 61 43 70.4 IgG [55]
Outbreak and non-febrile 2002 Bekasi 145 65 44.8 IgG [56]
2001 Bogor 70 35 50.0 IgG [56]
1998–1999 Yogyakarta 76 34 44.5 IgG [55]
Median (Outbreak) 1998–2015 Indonesia 47.4 (0.0–73.1) Present study
Median (Total) 1969–2015 Indonesia 18.5 (0.0–73.1) Present study
HI Haemagglutination inhibition assay, IgG Immunoglobulin G, PRNT Plaque reduction neutralization tests
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Table 4 Chikungunya virus genotypes circulating in Indonesia
Year Location Setting Number of sequences Genotype (n) Accession number (GenBank) Reference
2015 Jambi Non-outbreak 8 Asian KX097981-KX097988 [86]
2016 Bali Outbreak 6 Asian KY885022-KY885027 [79]
2013 Indonesia Exported case 1 Asian KF872195 [85]
2012 Bali Exported case 1 Asian KM673291 [104]
2011 Various places Outbreak 28 ECSA (2), Asian (26) KJ729829-KJ729856 [13]
2011 Surabaya Ae. aegypti male 2 Asian AB678689-AB678690 [84]
2010–2011 Surabaya Non-outbreak 17 Asian AB678691-AB678695
AB678678-AB678688
[84]
2010 Indonesia Exported case 1 ECSA KC862329 [103]
2009 Indonesia Exported case 1 Asian FR846307 [99]
2007-2014a Indonesia Exported case 29 ECSA (6), Asian (23) KU561427-KU561432 and KU561436-KU561458 [23]
2008 Indonesia Exported case 2 ECSA (1), Asian (1) FJ445483, FJ445472 [20]
2007 Indonesia Exported case 1 Asian EU192143 [83]
2007–2008 Indonesia Exported case 7 Asian FJ807897, FJ807886-FJ807891 [101]
2007b Bandung Non-outbreak 3 Asian KT175539-KT175541 [82]
2000–2008 Bandung Non-outbreak 20 Asian KC879559-KC879578 [95]
1985 Indonesia Unknown 1 Asian HM045797 [77]
1985 Ambon Unknown 1 Asian AF192894 [109]
1983 Indonesia Unknown 1 Asian HM045791 [77]
ECSA East-Central South African gebnotype
a ECSA genotype was isolated during 2009–2010 only
b Sequences are part of non-structural gene
Fig. 4 Phylogenetic tree of 127 Indonesian Chikungunya viruses and 1589 reference sequences from GenBank. The phylogenetic tree was generated
using the maximum likelihood (ML) method available in the Randomized Axelerated Maximum Likelihood (RAxML) program with General Time
Reversible and gamma substitution model (GTR + Γ). The tree shows the position of ten viruses of East/Central/South African (ECSA) genotype and 120
of Asian genotype from Indonesia relative to other viruses isolated worldwide
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studies published from 2013 onwards reported that the
percentage of asymptomatic chikungunya was more than
30% [25].
Our systematic review indicates that the median
seroprevalence of CHIKV-specific IgG antibodies was
18.5% (range 0.0–73.1%) among the total population in
all settings. However, from an epidemiological perspec-
tive, data from non-febrile subjects collected in a
non-outbreak setting is the best representation of the
true seroprevalence of CHIKV infection. The median
seroprevalence of anti-CHIKV IgG in this population
was 12.7% (range 0.0–26.8%) in Indonesia. This figure is
higher than the estimated seroprevalence of anti-CHIKV
IgG antibodies in Malaysian adults, which is at 5.9%
[115]. As predicted, the median seroprevalence of IgG
antibodies among healthy residents living in post-outbreak
areas is much higher (approximately three times higher)
compared to healthy residents in non-outbreak areas
(median 44.8%, range 55.5–50.5% vs. median 12.7%, range
0.0–26.8%). This finding is comparable with other out-
break investigations, including 20.0% in Brazil (2016)
[116], 26.8% in Thailand (2014) [117], 37.2% in Mayotte,
Indian Ocean (2006) [118] and 67.9% in India (2007)
[119]. The variability between these estimates is
Fig. 5 The maximum clade credibility (MCC) tree of Indonesian Chikungunya virus. The tree was generated using the Bayesian Markov chain
Monte Carlo (MCMC) method as implemented in BEAST using General Time Reversible (GTR) evolution model from E1 sequences. In the analysis,
127 Indonesian chikungunya viruses and 53 representative reference sequences from GenBank were included. All Indonesian Chikungunya
viruses, isolated locally (red front) or isolated in neighboring countries (blue front) are grouped into Asian and East/Central/South African
(ECSA) genotype
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influenced by several factors such as serum collection time
relative to outbreak, criteria of sample selection (whether
asymptomatic residents during the outbreak are included
or excluded) and the location of the serosurvey relative to
the epicentrum of outbreak.
Surprisingly, no chikungunya-associated deaths have
been recorded in Indonesia since this disease was offi-
cially recognized by MoH of Indonesia in 1973 [48].
Since 2004, chikungunya has been included in the
National Diseases Surveillance run by the MoH and has
been reported in the Annual Report of Indonesia Health
Profile, the formal annual report from MoH of
Indonesia, since 2005 [48]. Although a substantial
incidence rate has been reported, no deaths have been
recorded since then. In the National Guideline of Pre-
vention and Control of Chikungunya from MoH [68],
there is no clear criteria for assessing or reporting
chikungunya-related deaths that should be included in
the surveillance system. Unsurprisingly, this lack of
guidance has led to no reported deaths from chikun-
gunya in Indonesia; and this number is probably due to
underreporting of fatal chikungunya cases within the
current passive surveillance system. In fact several stud-
ies in India [120, 121], Mauritius [12] and Brazil [122,
123] during ECSA genotype outbreaks and in Dominican
Republic [124] during an Asian genotype outbreak re-
vealed an increase in the mortality rate, with deaths not
adequately identified by passive surveillance systems. In
addition, those studies revealed an increase of excess
mortality [12, 120, 122–124] indicating that the actual
proportion of chikungunya-associated deaths is underes-
timated in many settings. In Indonesia, during the
2008–2009 chikungunya outbreaks, there were 137,655
chikungunya cases officially reported to MoH, with no
reported death. In addition, given the fact that the
illnesses caused by CHIKV and DENV are clinically in-
distinguishable and not all reported dengue cases in
Indonesia are confirmed by laboratory testing, leads to
Table 5 Exported chikungunya cases originating from Indonesia
Year(s) Country of reporting Number of cases Diagnosis method Genotype (n) Reference
2013–2014 Australia 47 IgM, IgG, RT-PCR and isolation Unknown [89]
2013 Russia 1 RT-PCR, isolation and sequencing Asian (1) [85]
2013 New Caledonia 1 RT-PCR and sequencing Asian (1) [102]
2012–2014 Taiwan 23 RT-PCR, isolation and sequencing Asian (15) and unidentified (8) [23]
2012–2013 Australia 34 IgM, IgG, RT-PCR and isolation Unknown [88]
2012 Germany 1 Isolation and sequencing Asian (1) [104]
2011–2012 Australia 2 IgM, IgG, RT-PCR and isolation Unknown [87]
2010–2011 Australia 32 IgM, IgG, RT-PCR and isolation Unknown [106]
2011 New Caledonia 2 Serology Unknown [98]
2010 Brazil 1 IgM and IgG Unknown [94]
2010 Brazil 1 IgM and HI test Unknown [97]
2010 Japan 1 IgM and RT-PCR Unknown [90]
2010 Netherlands 1 Isolation and sequencing ECSA (1) [103]
2009–2010 South Korea 3 IgM Unknown [92]
2009–2010 Australia 7 IgM, IgG, RT-PCR and isolation Unknown [105]
2009–2010 Taiwan 16 RT-PCR, isolation and sequencing Asian (8), ECSA (6) and unidentified (2) [23]
2009 Japan 3 IgM and PRNT Unknown [91]
2009 France 1 IgM, RT-PCR and sequencing Asian (1) [99]
2008–2009 Australia 2 IgM, IgG, RT-PCR and isolation Unknown [108]
2009 Singapore 3 IgM, RT-PCR and sequencing Asian (1), ECSA (1) [20]
2007 Australia 3 IgM, IgG and RT-PCR Unknown [107]
2007 Taiwan 1 RT-PCR, isolation and sequencing Asian (1) [83]
2006–2009 Taiwan 7 RT-PCR, isolation and sequencing Asian (7) [101]
2006 Europe 1 IgM, IgG or RT-PCR Unknown [93]
1989 Australia 1 IgM, IgG and isolation Unknown [100]
ECSA East/Central/South African genotype, HI Haemagglutination inhibition, IgG Immunoglobulin G, IgM Immunoglobulin M, PRNT Plaque reduction neutralizing
test, RT-PCR Reverse transcription polymerase chain reaction
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the possibility that deaths occur due to chikungunya
which may be wrongly attributed to dengue as a conse-
quence of the prioritization of dengue surveillance.
Chikungunya has been included in the Annual Report of
Indonesia Health Profile since 2005 [48, 56–65], but was
excluded in the 2016 MoH Annual Report [125]. In the
2017 Annual Report, only 126 chikungunya cases were
reported to MoH, which dropped from 1702 cases that
were reported in 2016 [126]. These points reflect that
chikungunya is not a priority disease in Indonesia and
that there is poor chikungunya surveillance and an in-
sufficient reporting system in Indonesia. If fact, in some
studies, higher fatality rate for chikungunya was reported
compared to dengue [122, 127, 128]. Therefore, the
MoH should provide clear criteria for chikungunya-
associated death in the national guidelines and institute
a clear reporting system. In addition, in outbreaks, active
surveillance might be required to reduce underreporting
of chikungunya deaths in the country.
To date, two genotypes of CHIKV have been isolated
in Indonesia (Asian and ECSA). Viruses of the West
African genotype have not yet been isolated from
Indonesia. Viruses of the Asian genotype were first
isolated in Indonesia 35 years ago [76]. The ECSA
genotype however was identified for the first time in
2008 [20, 100] and at the same time this genotype
caused several major outbreaks in Southeast Asia coun-
tries [16, 100, 129]. This suggests that chikungunya out-
breaks that occurred prior to 2008 in Indonesia were
associated with viruses of the Asian genotype.
A phylogenetic analysis revealed that the ECSA viruses
sampled from Indonesia during 2008–2011 are closely
related with viruses that caused contemporaneous out-
breaks in Southeast and East Asian countries, such as
Malaysia (2008–2009) [129], Singapore (2008) [19, 20],
Thailand (2008–2009) [16–18], and China (2010) [130].
This suggests that the viruses in Indonesia may have
been introduced from another country in Southeast
Asia, most likely Malaysia [13]. In 2008, a nationwide
chikungunya outbreak occurred in Malaysia, which was
found to be caused by viruses of the ECSA genotype
[129]. In the same year ECSA viruses were also reported
in Indonesia [20, 100] and continued to be sampled until
2011 [23]. Furthermore, our phylogenetic analysis re-
vealed that the ECSA viruses that circulated in Southeast
Asia, including Indonesia, were introduced from India
and Sri Lanka, where CHIKV circulated in 2005–2007
and infected more than 1.3 million persons during
2005–2006 in India alone [14].
Our data, together with other evidence, suggest that
the introduction of the ECSA genotype to Indonesia
may be the reason for the large chikungunya outbreak
reported between 2009 and 2010 in the country (Fig. 2).
First, the Asian genotype had been the dominant
genotype of Indonesia and had circulated for several de-
cades. However, the annual number of cases never
exceeded more than 10,000 cases prior to 2009. Second,
the ECSA was first reported in Indonesia in 2008, and
had not been isolated in the multiple studies of Indones-
ian CHIKV (conducted both locally and in neighboring
countries) prior to this time [81, 82, 94, 100]. This
evidence indicates a time relationship between the intro-
duction of the ECSA genotype into Indonesia and a
sharp increase of reported chikungunya cases. Third,
within the same time-frame, nationwide outbreaks of
chikungunya associated with viruses of the ECSA geno-
type occurred in Malaysia [129], Singapore [19] and
Thailand [16]. The ECSA viruses isolated from these
outbreaks are all closely related, indicating that these
outbreaks were probably caused by the same type of
virus that then dispersed throughout the region and
likely into Indonesia as well (Fig. 5). Other scientific
evidence also supports this finding of chikungunya
outbreaks in Southeast Asian countries during that
time-frame being driven by the emergence of the same
strain of ECSA [131]. In addition, MoH data reveal that
the highest number of CHIKV cases in 2009 were
reported in Bangka Belitung and provinces in Sumatera
Island (Jambi, South Sumatera, Lampung, Bengkulu,
North Sumatera and Aceh) [62]. These provinces are in
close geographical proximity to Malaysia and Singapore
(Fig. 3). Finally, evolutionally analysis reveals that ECSA
viruses isolated from Indonesia are closely related to
those viruses associated with massive outbreaks in
Malaysia, Singapore and Thailand (Fig. 5). This possibil-
ity is also supported by the fact that ECSA is more
adaptive to Ae. albopictus due to a mutation in the enve-
lope protein gene (E1-A226V) [132]. This mutation as-
sociated with a significant increase in viral infectivity for
Ae. albopictus, and led to more efficient viral dissemin-
ation [132]. In the area where both Ae. aegypti and Ae.
albopictus are endemic, like Indonesia, introduction of
ECSA viruses could cause a massive outbreak. This evi-
dence, in aggregate, suggests that the massive outbreaks
in Indonesia during 2009 and 2010 were caused by the
introduction of the ECSA genotype to the country.
There are some limitations of this study that should be
discussed. First, full-texts of some potential references
that assess the seroprevalence of the anti-CHIKV anti-
bodies were not available, especially those published
prior to 1985 [133–142]. Second, in the seroprevalence
section of this paper, we included a study that utilized
the HI test as a diagnostic method [50]. This test is quite
sensitive for detecting alphavirus antibodies; however,
cross-reactions often occur among the viruses of the
same group. Nevertheless, a great majority of sera from
this study reacted with only one of the alphaviruses by
the HI test and therefore the results from that study
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were valid. Third, the collection time of the sera, relative
to time of infection, among studies were not the same.
This might influence the percentage of samples that
were positive for IgM and IgG among studies. For ex-
ample, an outbreak investigation in Yogyakarta reported
a significantly lower of seroprevalence of anti-CHIKV
IgM and a higher IgG seroprevalence compared to other
studies, as the investigation was conducted after the
resolution of the outbreak [54]. Fourth, in Indonesia the
absence of serological surveillance means that the pre-
cise numbers of chikungunya cases reported to the MoH
during outbreaks are often diagnosed clinically only.
Fifth, some of the known CHIKV of the Asian genotype,
that have been isolated previously, were not available in
GenBank [101]. Finally, some CHIKV sequences origin-
ating from Indonesia may have been reported as deriving
from elsewhere, if a returning traveller had an incom-
plete or inaccurate travel history. Studies may have failed
to report Indonesia as the country of origin of isolated
viruses, and instead, reported the country in which the
virus was isolated as the origin [20]. Despite these limi-
tations, this study is, to the best of our knowledge, the
first systematic review on CHIKV infection in Indonesia.
Strengths also include a search strategy that avoided
missing potential references and Indonesian CHIKV
sequences. In addition, this study is also able to provide
the incidence rate of chikungunya for a 16-year period
using the National Diseases Surveillance database from
the MoH.
Conclusion
Evidence suggests that CHIKV has circulated in most of
the Indonesian archipelago for at least 50 years, despite
the first virologically confirmed outbreak being recorded
as recently as 1982. Although anti-CHIKV IgM and IgG
seroprevalence is high and two massive nationwide
outbreaks have been recorded in Indonesia, no deaths
have been reported. The lack of reported deaths possibly
reflects under-reporting of fatal cases in the country
using the current surveillance system. Data from both
locals and travelers revealed that the Asian genotype has
been identified in Indonesia for more than 30 years,
while viruses of the ECSA genotype were sampled only
during the 2008–2011 period. A phylogenetic analysis
reveals that the ECSA viruses sampled in Indonesia dur-
ing this period are closely related to viruses that have
circulated in neighboring Southeast Asian countries, as
well as China and South Korea, within the same time-
frame. It is likely that ECSA viruses were introduced to
Indonesia from a neighboring country within the region,
in 2008. Spatio-temporal, phylogenetic and evolutionary
data suggest that this genotype was likely associated with
the large 2009–2010 chikungunya outbreak in Indonesia.
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